

Natpara[®] (parathyroid hormone) – Drug shortage

- The [drug shortage](#) of Takeda's [Natpara \(parathyroid hormone\)](#) injection is ongoing due to requirements related to complying with good manufacturing processes. Natpara has been unavailable for at least 90 days.
- In September 2019, Takeda announced a voluntary patient-level recall of all doses of Natpara due to a potential issue related to rubber particulates originating from the rubber septum of the Natpara cartridge. Takeda is working with the FDA to resolve this issue.
- Per Takeda, Natpara is only available through a [Special Use Program](#) that allocates Natpara to patients facing a life-threatening condition. The estimated availability of Natpara to the broader patient community is not known at this time.
- Natpara is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.

Product Description	Strength	NDC#
Natpara (parathyroid hormone) injection	25 mcg	68875-0202-01; 68875-0202-02
	50 mcg	68875-0203-01; 68875-0203-02
	75 mcg	68875-0204-01; 68875-0204-02
	100 mcg	68875-0205-01; 68875-0205-02